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5290 JOURNABSTRACT: The aim of this study was to characterize and evaluate a novel oral insulin
nanoparticulate system based on alginate-dextran sulfate core, complexed with a
chitosan-polyethylene glycol-albumin shell. Insulin-loaded nanospheres (25, 50,
100 IU/kg) administered orally to diabetic rats reduced glycemia in a dose dependent
manner. This effect lasted over 24 h with a maximal effect after 14 h. Nanospheres
increased insulin plasma level and improved glycemic response to an oral glucose
overload. After 4 days oral administration (50 IU/kg/day), the metabolic status of
diabetic rats improved with a reduction in water intake, urine excretion and proteinuria.
FITC-insulin-loaded nanospheres administered to an isolated intestinal loop were taken
up by the intestinal mucosa. They strongly adhered to villus apical enterocytes and
markedly labeled Peyer’s patches. It is concluded that nanospheres preserve insulin and
exert an antidiabetic effect after oral administration. This is explained by a protective
effect against proteolytic enzymes by the albumin coating, by the mucoadhesive proper-
ties of chitosan-polyethylene glycol, and by the possibility of chitosan reversibly altering
tight junctions leading to an improved absorption of insulin. This formulation demon-
strates beneficial effects on diabetic symptoms and will be of interest in the treatment of
diabetes with oral insulin.  2008 Wiley-Liss, Inc. and the American Pharmacists Association J
Pharm Sci 97:5290–5305, 2008Keywords: diabetes; insulin delivery; biomaterials; nanospheres; oral absorptionINTRODUCTION
Diabetes mellitus is a metabolic illness requiring
strict glycemic control to reduce its progression
and complications. Insulin replacement therapy
provides the most effective means for glycemic
control. Replicating physiological insulin secre-nce to: Catarina P. Reis (Telephone: þ351-
: þ351-239855099;
reis@ci.uc.pt)
aceutical Sciences, Vol. 97, 5290–5305 (2008)
, Inc. and the American Pharmacists Association
AL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DEtion as a means of restoring normal metabolism,
minimizes complications, and has thus becomes
the essential goal of diabetes treatment.1
Amongst alternative routes for insulin admin-
istration, the oral route is potentially the most
convenient and physiological. After gastrointest-
inal absorption, insulin undergoes a first hepatic
bypass, thus triggering a primary effect by inhibit-
ing hepatic glucose production.1 However, peroral
bioavailability of insulin is relatively low mainly
due to high proteolytic activity in the gut and low
permeability of the intestinal epithelium.2 As with
other peptides, insulin shows a poor physical andCEMBER 2008
NANOPARTICULATE BIOPOLYMERS DELIVER INSULIN 5291chemical stability and a relatively short plasma
half-time.3 Several strategies to overcome these
barriers for perorally administered insulin
include the addition of enzyme inhibitors4 and/
or permeation enhancers,5 chemical modifica-
tion,6 cell penetration peptides,7 vitamin B12
8 or
cyclodextrin conjugation,9 polymeric carriers,2,10–12
liposomes13 or a colon targeting of the drug
delivery system where the enzymatic activity is
relatively low.14 A promising strategy is the use of
multifunctional polymers exhibiting permeation
enhancing and mucoadhesive properties.15 The
interest of using natural materials such as
alginate as part of drug development has inc-
reased in the past two decades.
Alginates are naturally occurring polymers and
are known to form a reticulated structure when in
contact with calcium ions. This particular char-
acteristic has been used to produce sustained
release particulate systems for a variety of drugs,
proteins and even cells.16,17 Previously, we devel-
oped an insulin formulation18 contained alginate
as matrix polymer and dextran sulfate as additive
polymer. Dextran sulfate prevented insulin
release at low pH, however, the entrapped insulin
was rapidly released when nanospheres were
transferred to intestinal fluid.18 Moreover, the
entrapped insulin showed a high sensitivity to
pepsin attack, being rapidly degraded in simu-
lated gastric fluid containing pepsin. In vivo
studies also showed that alginate-dextran sulfate
nanospheres were ineffective in reducing glyce-
mia following oral administration to fasted
diabetic rats. Thus, coating strategies were
developed to improve enzymatic resistance and
thus improve insulin oral absorption. The first
strategy involved applying chitosan as coating
material. Chitosan, a biocompatible polysacchar-
ide was selected to several reasons. Polycationic
polymers such as chitosan can be used to increase
the stability of polyanionic alginate nanospheres
and to minimize the loss of encapsulated mate-
rial.19 Secondly, chitosan exerts mucoadhesive
properties and facilitates drug absorption by
localizing drug around absorptive cells and by
prolonging drug residence in the gut. Finally,
chitosan is an effective permeability enhancer
because it reversibly alters the tight junctions by
its depolymerizing action on cellular F-actin and
the tight junction protein ZO-1.20 In our case,
chitosan coating decreased encapsulation effi-
ciency of insulin but in vitro release was now
controlled in contrast with uncoated nanopsheres.
As well, and as been observed in a similar systemDOI 10.1002/jps JOURNAbut when using microspheres,21 chitosan-coated
alginate-dextran sulfate core nanospheres were
still highly sensitive to pepsin and did not reduce
glycemia during in vivo assays. Albumin was then
added as a second coating material. Albumin
coating decreased encapsulation efficiency but for
the first time, we observed insulin protection
against pepsin. In vivo hypoglycaemic effect was
even more pronounced when PEG was applied as
a stabilizing polymer. Albumin was selected as a
shell component for the possible protection of
insulin against proteolytic enzymes in the gastro-
intestinal tract. As stabilizing polymer, PEG was
selected for several reasons. PEG is nontoxic, is
known to increase stability of polymeric nano-
particles22 and it improves the transport of large
proteins across nasal and intestinal barriers.23,24
PEG can also improve peptide physicochemical
and biopharmaceutical properties.25
The new nanosphere formulation described in
the present report consists of an alginate-dextran
sulfate core containing insulin, coated with
chitosan-polyethylene glycol and finally albumin.
Nanospheres were physicochemically character-
ized (diameter, zeta-potential, insulin loading)
and insulin release investigated under simulated
gastrointestinal conditions. Biological efficacy
was analyzed in diabetic rats after a single and
repeated oral administration. Finally, in order to
examine the mechanism of intestinal uptake,
insulin was labeled with fluorescein isothiocya-
nate (FITC) and the uptake of FITC-insulin-
loaded nanospheres was visualized and quantified
after intraluminal administration to an isolated
intestinal segment. Water and electrolyte turn-
over during a 4 days treatment with oral insulin-
loaded nanospheres was also evaluated.MATERIALS AND METHODS
Materials
Low viscosity sodium alginate (viscosity of 2%
solution at 258C, 250 cps) was purchased
from Sigma (St. Louis, MO). Chitosan (50 kDa),
albumin, pepsin and streptozotocin were pur-
chased from Sigma–Aldrich Chimie (L’Isle
d’Abeau Chesnes, France). Setacarb calcium
carbonate was obtained from Omya (Orgon,
France). Paraffin oil was supplied by Vaz Pereira
(Lisbon, Portugal). The emulsifier, Span 80,
dextran sulfate (5 kDa) and PEG 4000 were
purchased from Fluka, Chemie GmbH (Buchs,L OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 2008
5292 REIS ET AL.Switzerland). Insulin was kindly donated by
Hospitais da Universidade de Coimbra (Actrapid
Insulin1, 100 IU/mL from Novo Nordisk, Bags-
vaerd, Denmark).Preparation of Insulin-Loaded Nanospheres
Nanosphere preparation involved formulation of
an alginate-dextran sulfate core, through nanoe-
mulsion dispersion followed by triggered ins-
tantaneous particle gelation.18 The following
formulation was optimized in terms of insulin
release profile and the ability of the particles to
provide resistance against pepsin. A sodium
alginate (2%, w/v), dextran sulfate (0.75%, w/v)
solution was prepared by stirring (100 rpm)
overnight. Following stationary deaeration for
1 h, insulin was added and dissolved (100 IU/mL,
10 mL). An aqueous suspension of ultrafine
calcium carbonate (5%, w/v) was added at
calcium-alginate ratio of 7% (w/w), and the
dispersion was emulsified within paraffin oil
facilitated by Span 80 emulsifier (1.5% v/v) at
high speed (1600 rpm). After 15 min, gelation was
induced by addition of 20 mL paraffin oil contain-
ing glacial acetic acid (acid-calcium molar ratio, 3)
to solubilize calcium dispersed in the alginate-
dextran nanodroplets. After 60 min, an acetate
buffer solution (pH 4.5) (made according United
States Pharmacopeia, USP XXVIII) with dehy-
drating solvents (acetone, isopropanol, and
hexane)26 was added to the oil-nanoparticle
suspension and nanospheres were recovered by
centrifugation (12500g during 10 min). The coat-
ings were applied simply through electrostatic
interaction. Chitosan-PEG solution at pH 4.5
(PEG-chitosan mass ratio of 5 with high calcium
level at 1.5% (w/v)) was added to uncoated
nanospheres under magnetic stirring during
30 min. Then, the supernatant containing
unbound polymer was decanted and albumin-
coating (1% albumin (w/v) in 100 mL at pH 5.1)
applied to chitosan-PEG nanospheres under
magnetic stirring during 30 min. Unbound coat-
ing protein contained in the supernatant was
decanted. Insulin-free nanospheres (empty nano-
spheres) were also prepared.Characterization of Insulin-Loaded Nanospheres
Size distribution analysis was performed by laser
diffraction spectrometry using a Coulter LS130
granulometer (Beckman Coulter, Inc., Fullerton,JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 200CA). Mean diameters of aqueous suspensions
were determined in triplicate and size distribution
was represented by number. Surface charge was
determined by laser doppler anemometry on a
Malvern Zetasizer 3000HS (Malvern Instru-
ments, Worcestershire, UK) at pH 4.5 and 258C,
the result of which is expressed as Zeta Potential.
For scanning electron microscopy (SEM), insulin-
loaded nanospheres were mounted on metal stubs
using double-sided adhesive tape, drying in a
vacuum chamber, sputter-coating with a gold
layer and viewing under a scanning electron
microscope (JSM-840, Jeol Instruments, Tokyo,
Japan) to characterize shape and morphology and
confirm particle size.Determination of Encapsulation Efficiency of Insulin
Encapsulation efficiency was determined after
chitosan-PEG-albumin-coating by analyzing fil-
trate, wash and dehydration solutions using
insulin enzyme-linked-immuno-sorbent assay
insulin kit (ELISA, Mercodia, Sweden) at
450 nm. Encapsulation efficiency (%) was deter-
mined by the following equation:
Encapsulation efficiency ð%Þ
¼ Initial insulin
  lost Insulin
Initial insulin
 100
Initial insulin added to formulate nanospheres.In Vitro Release of Insulin Under Simulated
Gastrointestinal Conditions
In vitro release behavior was assayed by incubat-
ing 5 mL of nanosphere suspension in 5 mL of HCl
buffer at pH 1.2 (USP XXVIII), under magnetic
stirring (100 rpm, 2 h) at 378C, simulating
stomach conditions without enzymes under sink
conditions. The medium volume was calculated to
ensure that sufficient volume be available to
dissolve the insulin from the nanospheres. Sam-
ples at appropriate intervals were withdrawn and
protein assayed using HPLC where the mobile
phase was water (A): acetonitrile (B) with 0.04%
trifluoroacetic acid with linear gradient B 30–40%
over 5 min, flow rate 1.2 mL/min at 258C. A
reversed-phase X-Terra C-18 column, 5 mm,
4.6 mm 250 mm (Waters Corporation, Milford,
MA, USA), with a Purospher1 STAR RP-18 pre-
column, 5 mm, 4 mm 4 mm (Merck, Darmstadt,
Germany) was employed. The UV detector was set8 DOI 10.1002/jps
NANOPARTICULATE BIOPOLYMERS DELIVER INSULIN 5293at 210 nm and HPLC analysis carried out 278C.21
An insulin retention time around 5 min was
obtained. To simulate the progress of nanospheres
moving from the stomach into the upper small
intestine, the buffer was changed to higher pH
after 120 min. Nanospheres were centrifuged,
then resuspended in 10 mL phosphate buffer at
pH 6.8 (USP XXVIII), under magnetic stirring
(100 rpm) at 378C during 840 min. Samples at
appropriate intervals were withdrawn and insulin
assayed by HPLC. A calibration curve was
prepared for each medium using fresh insulin.
Experiments were performed in triplicate. Cumu-
lative insulin release was then calculated as
percentage of initial insulin content.Insulin Molecular Integrity Under Simulated
Gastrointestinal Conditions
Insulin molecular integrity was evaluated by
HPLC after 1 mL nanosphere (8.5 IU of insulin/
mL) matrix dissolution with 5 mL of sodium
citrate (55 mM) in phosphate buffer pH 7.4 (USP
XXVIII). Insulin was quantified initially, and
after 2 h incubation in simulated gastric fluid
containing pepsin at pH 1.2 (USP XXVIII) in a
shaking water bath at 378C and 100 rpm. Insulin-
loaded nanospheres were recovered by centrifu-
gation and transferred to citrate solution with
stirring for 1 h, then aliquots collected, centri-
fuged and analyzed by HPLC (same conditions as
previous experiment). HPLC chromatograms
were collected and nonencapsulated insulin
served as reference. Assays were conducted in
triplicate. Intact insulin has a retention time
around 5 min using same HPLC conditions as
previous assay. Enzyme resistance was verified by
insulin content after enzyme incubation as
percentage of initial insulin content.In Vivo Efficacy of Insulin-Loaded
Nanospheres on Diabetic Rats
Male Wistar rats (250 g) were housed in a 12–12 h
light–dark cycle, constant temperature environ-
ment of 228C, relative humidity 55% and allowed
free access to water and food during acclimatiza-
tion. Animals received standard laboratory chow
diet (UAR, Villemoisson-sur-Orge, France) and
tap water, available ad libitum. All treatments
began between 8.00 and 9.00 h. All experiments
were carried out in accordance with the European
Community Council Directive (86/609/EEC). ToDOI 10.1002/jps JOURNAminimize the diurnal variance of blood glucose, all
experiments were performed in the morning.
Diabetes was induced with intravenous injection
of 65 mg/kg streptozotocin in citrate buffer (pH
4.5) as previously described.10 Ten days after the
treatment, rats with frequent urination, loss of
weight and blood glucose levels higher than
300 mg/dL were included in experiments. Blood
glucose levels were determined by glucose
oxidase/peroxidase method using a glucometer
(Accucheck Go, Roche, Strasbourg, France).
In order to verify that the particles contained
bioactive insulin, insulin-loaded nanospheres
were injected subcutaneously to fasted diabetic
rats (4 IU/kg body weight). Nonencapsulated
insulin (4 IU/kg) was administered as control.
Glycemia in blood samples withdrawn from the
tail vein was measured before insulin injection
and at intervals to 8 h. Rats were fasted 12 h prior
to dosing, during the experiment and fed there-
after.
In order to investigate the effects of oral insulin-
loaded nanospheres, 12 h fasted diabetic rats were
gavaged with insulin-loaded nanospheres (25, 50,
or 100 IU/kg) or empty nanospheres as control.
Glucose was measured on a drop of blood from the
tail vein before and at different intervals up to
24 h after oral nanosphere administration. Serum
glucose time course was plotted, and the area
below the 100% cut-off line determined using the
trapezoidal method during 0–14 h. Pharmacolo-
gical availability of peroral delivered insulin
(AUC0–8h) was determined based on 100% avail-
ability of the nanosphere suspension adminis-
tered subcutaneously at a dose of 4 IU/kg. In the
previous study,18 nanospheres showed 100%
pharmacological availability in comparison to
insulin solution when administered subcuta-
neously. In order to eliminate potential interfer-
ences of the encapsulation process and the role of
polymers unloaded nanospheres were then
applied as controls. Finally, in order to confirm
albumin and PEG effects, chitosan-coated algi-
nate-dextran core nanospheres without albumin
and PEG, were orally administered to fasted
diabetic rats at dose level of 50 IU/kg. The same
assay was performed with nonencapsulated insu-
lin and water as negative controls. Serum glucose
time course was plotted.
The effect of insulin-loaded nanospheres on
postprandial rise in blood glucose was tested.
Empty or insulin-loaded nanospheres (50 IU/kg)
were given orally 10 h before the glucose gavage.
Blood glucose level was measured as describedL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 2008
5294 REIS ET AL.previously at 0, 20, 40, 60, 90, 120, and 180 min
after glucose gavage (2 g/kg body weight).
Plasma insulin levels were also determined
after oral dosage of insulin-loaded nanospheres.
Twelve hours fasted diabetic rats were anaesthe-
tized with ketamine and xylazine. Blood samples
were collected before oral administration of
insulin-loaded nanospheres (50 IU/kg) and 4, 8,
and 12 h thereafter, then centrifuged, and the
plasma was stored at 208C. Plasma immunor-
eactive insulin was measured by radioimmuno-
metric assay (Insulin-CT kit from CIS Bio
International, Gif-sur-Yvette Cedex, France) for
up to 12 h.Intestinal Uptake of Insulin-Loaded Nanospheres
Fluorescein isothiocyanate (FITC)-labeled insu-
lin-loaded nanospheres (50 IU/kg) were adminis-
tered in an in situ isolated intestinal loop. Rats
were fasted overnight and anesthetized with
ketamine (100 mg/kg). After laparotomy, a
30 cm ileal loop, situated above the ileocaecal
valve, was isolated from the digestive tract by
a ligature at each side. A 2 mL suspension of
FITC-insulin-loaded nanospheres (50 IU/kg) was
injected in the intestinal lumen of this ileal
segment. The volume of the formulations is an
important factor on the gastrointestinal tract
particle distribution.27
The animals (6 per group) were sacrificed at
time intervals up to 8 h after the intra-luminal
injections. Blood from the mesenteric vein, the
intestinal content and the intestinal mucosa were
removed and frozen until analysis. Biopsies of the
follicular (Peyer’s patches) and the nonfollicular
mucosa were performed at the same time inter-
vals. Tissue samples were embedded in a cryostat
medium (Tissue Tek, Miles Diagnostics, Elkhart,
Indiana, USA), cryofixed and 10 mm thick frozen
sections were prepared using a cryostat (Leica,
CM3050 S, France), and sections observed under
fluorescence microscope (Olympus DP70, Rungis,
France). As well, micrographs were taken with
a BioRad MRC-1024 confocal laser scanning
microscope equipped with an argon/krypton laser
(Bio-Rad Laboratories GmbH, Munich, Germany).
The excitation was performed using l¼ 488 nm
for green fluorescence. Images were processed
using Volocity1 software (Improvision Germany,
Tuebingen, Germany).
Fluorescent activity in mesenteric blood, gut
contents and mucosa homogenates was measured
by spectrofluorometry using a fluorescence spec-JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 200trophotometer (BioRad, VersaFluorTM, Marnes-
la-Coquette, France). The fluorescence measure-
ment was performed at an excitation wavelength
of 480 nm and an emission wavelength of 520 nm.Water and Electrolyte Turnover During 4-Day
Treatment With Oral Insulin-Loaded Nanospheres
Twelve animals were maintained in individual
metabolic cages under standard laboratory con-
ditions. The individual metabolic cages permitted
the quantification of the exact amounts of water
and food consumed, as well as volume of urine
which was collected in a bottle. Following a 24 h
familiarization period, rats were divided into two
groups of six rats, and treated orally either with
insulin-loaded nanospheres (50 IU/kg) or empty
nanospheres for 4 successive days. On the last day
of treatment, water and food intake were mea-
sured and urine was collected. Insulin-loaded
nanospheres or empty nanospheres were admi-
nistered each day after a 6 h fast.Statistical Analysis of In Vivo Data
Results were expressed as means standard
deviation (SD) or means standard errors of
means (SEM). For group comparison, an analysis
of variance with a one-way layout was applied.
Significant differences in mean values were
evaluated by a Student’s t-test. For multiple
comparison group tests, a Bonferroni or a Dunnett
multicomparison test was applied, using Instat
2.00 Macintosh software (Graph Pad Software,
San Diego, CA). The differences were considered
significant when p< 0.05.RESULTS
Characterization of Insulin-Loaded Nanospheres
Insulin-loaded nanospheres showed a unimodal
size distribution with 90% of the particles having
a diameter less than 1842 nm, and 50% less than
812 nm as seen in Figure 1. Small agglomerates
were observed under SEM as seen in Figure 2
however agglomerates readily dispersed after
manual mixing. SEM images showed that indivi-
dual particles were mainly less than 1000 nm. The
charge of uncoated nanospheres was negative
(16 2 mV) as shown in Table 1 but addition of
polycationic chitosan coating reversed the charge
to positive (þ15 1 mV). Subsequent application
of albumin-coating reversed the charge once again8 DOI 10.1002/jps
Figure 1. Size distribution of albumin-chitosan-PEG
coated insulin-loaded nanospheres.
NANOPARTICULATE BIOPOLYMERS DELIVER INSULIN 5295to negative (12 5 mV), but less so, compared to
uncoated nanospheres. Application of PEG
reduced the negative charge of albumin-chitosan
coated nanospheres to 7 4 mV. Changes in the
zeta potential of the nanospheres indicate effec-
tive coating by the respective materials. Finally,
when insulin-loaded nanospheres were incubated
for 2 h at 378C with pepsin, nanospheres reverted
to positive (þ21 3 mV) due to hydrolysis of the
albumin coat. Thus, coating changes the physico-
chemical properties of the nanospheres.
Determination of Encapsulation Efficiency and
In Vitro Release of Insulin Under Simulated
Gastrointestinal Conditions
Encapsulation efficiency of insulin within the
nanospheres was high at 85 4%. In vitro releaseFigure 2. Scanning electron micrograph of chitosan-
PEG coated insulin-loaded nanospheres before BSA
coating. The bar represents 20 mm.
DOI 10.1002/jps JOURNAof insulin under simulated gastric and intestinal
conditions is illustrated in Figure 3. At low pH,
only 25% of the encapsulated insulin (2.1 IU/mL)
was released while an additional 45% of the insulin
was released when pH was changed to 6.8. Thus,
70% of the overall insulin was released after 960 min
assay and under simulated experimental conditions.
Insulin Molecular Integrity Under Simulated
Gastrointestinal Conditions
The resistance of insulin to pepsin was analyzed
by HPLC after exposure for 2 h at 378C. As
represented in Figure 4a, insulin shows one peak
at 5 min. Another peak at 8.3 min is related to an
insulin additive, metacresol, which is not present
in nanospheres because it is easily discarded
during the nanosphere recovery process. Insulin
released from nanospheres before pepsin incuba-
tion showed an insulin peak at the same retention
time (Fig. 4b). When nonencapsulated insulin was
exposed to pepsin, the insulin peak disappeared
(Fig. 4c), indicating proteolytic degradation. In
contrast, when insulin-loaded nanospheres were
exposed to pepsin, the insulin peak was maintained
showing that albumin coated nanospheres prevent
enzymatic degradation of insulin (Fig. 4d).
Glycemic Response of Diabetic Rats in
Response to a Subcutaneous Injection of
Insulin-Loaded Nanospheres
Blood glucose profiles following subcutaneous
injection of insulin-loaded nanospheres and non-
encapsulated insulin to diabetic rats at dose level
of 4 IU/kg are illustrated in Figure 5. Both
promoted a rapid and intense decrease of glycemia
with glucose levels approaching 13% of initial
values after 4 h. Then, blood glucose levels
increased reaching 40–50% of basal values at 8
h. In the untreated control group, blood glucose
level decreased slowly from 2 to 8 h, due to fasting.
There were no statistical differences between
groups treated with the same dose level of
nonencapsulated insulin and insulin-loaded nano-
spheres showing that the nanoparticulate insulin
was as effective as the same dose of free insulin,
demonstrating full retention of insulin activity.Glycemic Response of Diabetic Rats in Response to
Oral Administration of Insulin-Loaded Nanospheres
The glycemic response of insulin-loaded nano-
spheres was examined by orally dosing 12 h fastedL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 2008
Table 1. Zeta Potential of Insulin-Loaded Nanospheres and its Variation After Processing, Coating and Pepsin
Exposure
Nanosphere Production Zeta Potential (mV)
Uncoated nanospheres 16 2
Coating process
Chitosan-coated nanospheres þ15 1
Albumin-chitosan-coated nanospheres 12 5
Albumin-chitosan-PEG-coated nanospheres 7 4
Enzyme assay
Albumin-chitosan-PEG-coated nanospheres before pepsin incubation 7 4
Albumin-chitosan-PEG-coated nanospheres after pepsin incubation þ21 3
Data are meansSD of three experiments.
5296 REIS ET AL.diabetic rats with 25, 50, and 100 IU/kg or
empty nanospheres as control. As illustrated in
Figure 6A, insulin-loaded nanospheres decreased
glycemia in a dose-dependent manner in contrast
to rats treated with empty nanospheres. The
lowest insulin dose (25 IU/kg) was effective
(18%, p< 0.05) from 6 h while higher doses (50
and 100 IU/kg) significantly reduced glycemia
from 4 h (respectively by 17% and 21%, p< 0.05).
The glycemic reductions attained were 44
(p< 0.05), 55 (p< 0.05), and 76% (p< 0.01)
with 25, 50, and 100 IU/kg insulin-loaded nano-
spheres respectively. Rats were subsequently re-
fed after 14 h fast, then 24 h after the adminis-
tration of insulin-loaded nanospheres, glycemia
was still reduced by 21% (not significant),33
and 38% (p< 0.05) with 25, 50, and 100 IU/kg
insulin-loaded nanospheres respectively. Reduc-
tion of glycemia was not observed with insulin
solution, demonstrating that insulin alone cannot
be absorbed sufficient to elicit a biologicalFigure 3. In vitro release profile of albumin-chitosan-
PEG coated insulin-loaded nanospheres in simulated
gastric medium at pH 1.2 and intestinal medium at pH
6.8. Results are meansSD of three experiments.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 200response by the oral route in the absence of a
suitable carrier. As well, a hypoglycaemic effect
was not observed with empty nanospheres, the
decrease between 10 and 14 h being attributed to
the fast, over the experiment.Figure 4. Insulin HPLC chromatograms: (a) insulin
nonencapsulated as control (insulin retention time
around 5 min represented as dotted line); (b) insulin
extracted from nanospheres before pepsin incubation;
(c) insulin nonencapsulated as control after pepsin
incubation; (d) insulin extracted from nanospheres after
pepsin incubation. Peak around 2 min corresponds to
mobile phase peak for all situations.Peak around 8 min
in nonencapsulated insulin chromatogram corresponds
to an additive, metacresol, which is not present in
nanospheres. This additive is generally discarded after
nanospheres recovery process. Large band between 6
and 9 min corresponds to coating material of insulin-
loaded nanospheres.
8 DOI 10.1002/jps
Figure 6. (A) Glycemia after a single oral adminis-
tration of albumin-chitosan-PEG coated insulin-loaded
nanospheres: 25 IU/kg (full circles, n¼ 8), 50 IU/kg
(triangles, n¼ 9), and 100 IU/kg (squares, n¼ 8) or
empty nanospheres as control (empty circles, n¼ 9) in
fasted diabetic rats. Results are expressed as means
SEM. Mean basal values at T0 were 390 21 mg/dL. (B)
Areas under the curves (0–14 h) of each glycemia pro-
file. Statistically different from empty nanospheres:
p< 0.05; p< 0.01.
Figure 5. Glycemia after a subcutaneous adminis-
tration of insulin nonencapsulated (squares, n¼ 6)
and albumin-chitosan-PEG coated insulin-loaded nano-
spheres (triangles, n¼ 7) or saline (empty circles, n¼ 9)
in fasted diabetic rats. Insulin was administered at the
concentration of 4 IU/kg. Before the injections, glycemia
was 327 21 mg/dL. Results are expressed as means
SEM. Statistically different from saline control: (a)
p< 0.05; (b) p< 0.01; (c) p< 0.001.
DOI 10.1002/jps JOURNA
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a 14 h period (Fig. 6B) showed that 25, 50, and
100 IU/kg insulin-loaded nanospheres reduced
the areas by 24 (p< 0.05), 32 (p< 0.01), and 40%
(p< 0.01), respectively.
Pharmacological availability was calculated
based on AUC0–8h and summarized in Table 2.
Values ranged from 10% to 42% of subcutaneous
administration for doses of 100 to 25 IU/kg,
respectively.
To confirm albumin and PEG effects, chitosan-
coated alginate-dextran sulfate core nanospheres,
without albumin and PEG, were orally adminis-
tered to fasted diabetic rats. Figure 7 depicts blood
glucose profiles following oral administration.
Glycemia was not reduced for both nanospheres
and negative controls except at 6–8 h where the
fasting effect was observed for all tested groups.
Even after chitosan coating, alginate-dextran sul-
fate core nanospheres were ineffective in produ-
cing a pharmacological response, which is consistent
with previous results.21Glycemic Response of Diabetic Rats Treated by
Oral Insulin-Loaded Nanospheres to a Glucose
Tolerance Test (OGTT)
When diabetic rats were dosed orally with glucose
(2 g/kg body weight), glycemia increased reaching
a maximal level (347%, p< 0.001) after 40 min
(Fig. 8). Then glycemia decreased again to
180 min. When insulin-loaded nanospheres
(50 IU/kg) were administered 10 h before glucose
challenge, glycemia also increased but to a lesser
extent, attaining 246% of initial values 40 min
after glucose administration (p< 0.001), and
decreased slowly thereafter. Differences in
response between empty and insulin-loaded nano-
sphere treatments were significant statistically
(p< 0.05). Consequently, insulin-loaded nano-
spheres improved the response to a glucose
challenge.Insulinemia in Diabetic Rats Treated Orally With
Insulin-Loaded Nanospheres
After oral administration of insulin-loaded nano-
spheres (50 IU/kg), insulinemia increased with a
maximal effect 4 h after gavage by factor seven of
basal value as illustrated in Figure 9. The
detection kit used is known to have some cross-
reaction with rat insulin, which may explain the
low basal concentration due to weak residualL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 2008
Table 2. Pharmacological Availability of Insulin-Loaded Nanospheres Administered to Diabetic Rats, Calculated
from Glycemia Obtained After a Subcutaneous Administration of Free Insulin (4 IU/kg) and an Oral Administration of
Insulin-Loaded Nanospheres (25, 50, and 100 IU/kg)
Route Dose of Insulin (IU/kg) AUC0-8h Pharmacological Availability (%) tmax (h)
Subcutaneous 4 265 18 100 4
Oral 25 696 43 42 14
Oral 50 670 31 21 14
Oral 100 630 36 10 14
Data are meansSEM of 6–9 animals per group.
5298 REIS ET AL.insulin production which can occur in streptozo-
tocin induced diabetic rats. Basal insulin concen-
tration was 35.0 8.2 mU/mL (t¼ 0) but insulin
levels increased to 250.8 19.4 mU/mL (p< 0.001)
at 4 h following oral administration of human
insulin. At 8 h, plasma insulin level was still high
at 149.4 12.7 mU/mL (p< 0.001) and increased
again at 12 h, being 225.1 20.2 mU/mL
(p< 0.001). These results showed that insulin
absorption was markedly enhanced by the action
of insulin-loaded nanospheres.Intestinal Uptake of Insulin-Loaded Nanospheres
When FITC-labeled insulin-loaded nanospheres
(50 IU/kg) were administered to an in situ isolated
intestinal loop, a strong fluorescence appeared
after 5 min in the lumen (Fig. 10a). Fluorescent
label was strongly adherent to the apical part of
the villi and appeared as a film in close contact
with enterocytes (Fig. 10b). No labeling appearedFigure 7. Glycemia after a single oral administration
of chitosan-coated alginate-dextran core nanospheres
without albumin coating and PEG stabilizing effect:
50 IU/kg (full circles, n¼ 6), empty nanospheres (empty
circles, n¼ 6), nonencapsulated insulin (stars, n¼ 6)
and water (line, n¼ 4) as control in fasted diabetic rats.
Results are expressed as meansSEM.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 200in the lumen of the crypt nor in the crypt cells. In
addition, an intense fluorescent labeling was
present in the connective axis of the villi where
it probably reflects the presence of labeled insulin
inside vascular structures. Indeed, focused fluor-
escent points had deep intestinal location as
observed by confocal microscopy analysis, 30 min
after in situ administration (Fig. 11a and b). There
was a strong labelling of Peyer’s patches (Fig. 10c)
indicating a preferential uptake of insulin-loaded
nanospheres by these follicles.
In contrast, when FITC-labeled insulin in
solution was administered in the intestinal
lumen, lumen and villi remained unlabeled.
Occasionally, a very smooth material appeared
in the dome of Peyer’s patches.
Fluorescent activity in rat gut contents and
mucosa homogenates from isolated intestinal loopFigure 8. Blood glucose levels after an oral glucose
challenge (2 g/kg) performed 10 h after a single oral
administration of albumin-chitosan-PEG coated insu-
lin-loaded nanospheres (50 IU/kg) (triangles, n¼ 12) or
empty nanospheres (empty circles, n¼ 10) in fasted
diabetic rats. Results are expressed as meansSEM.
The value of glycemia before the administration of
nanospheres for all animals was 492 23 mg/dL. This
value decreased 54% and 1% after 10 h and before
glucose administration for animals dosed with albu-
min-chitosan-PEG coated insulin-loaded nanospheres
and empty nanospheres, respectively. Statistically
different from empty nanospheres: p< 0.05.
8 DOI 10.1002/jps
Figure 9. Insulinemia bar plot following oral admin-
istration of albumin-chitosan-PEG coated insulin-
loaded nanospheres (50 IU/kg) in diabetic rats fasted
for 12 h. Each value represents meanSEM (n¼ 14).
Mean basal values at time zero were: 35.0 8.2 mU/mL
(t¼ 0). Comparisons versus time zero: p< 0.05.
Figure 10. Fluorescence microscopy of tissu
5 min (a) and 30 min (b and c) after the intralum
PEG coated FITC-labeled insulin-loaded nano
intestinal segment. Note in (a) the presence of
lumen. Part (b), fluorescent material is adheren
and is present inside the core of the villus. P
Peyer’s patches. Magnifications: (a) 100; (b)
DOI 10.1002/jps JOURNA
NANOPARTICULATE BIOPOLYMERS DELIVER INSULIN 5299and mesenteric blood was measured by fluores-
cence spectrophotometry and is represented in
Figure 12. Strong FITC-fluorescence spreading
through gut content decreased over time. In
contrast, fluorescence of mucosal contents
progressively increased and achieved a max-
imum at 8 h. Concerning FITC-insulin levels in
mesenteric blood, a strong increase of fluores-
cence activity was observed over the experiment
demonstrating insulin passage through intest-
inal mucosa.e slices through the intestinal epithelium
inal administration of albumin-chitosan-
spheres (50 IU/kg) in an in situ isolated
fluorescent material inside the intestinal
t to the apical pole of enterocytes (arrow)
art (c), a strong fluorescent material in
200; (c) 100.
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Figure 11. Confocal microscopy of intestinal villi after 30 min of intraluminal
administration of albumin-chitosan-PEG coated FITC-insulin-loaded nanospheres in
an in situ isolated intestinal segment. The fluorescent labeling (arrow) represents
insulin-loaded nanospheres in the core of the villus (a). Lines indicate where the pictures
were taken and analyzed (b). The bar represents 25 mm in (a) and 38 mm in (b).
5300 REIS ET AL.Metabolic Status of Diabetic Rats After 4-Day
Treatment With Insulin-Loaded Nanospheres
Diabetes is generally characterized by several
metabolic parameters such as hyperphagia, poly-
dipsia and polyuria together with albuminuria
and proteinuria. As illustrated in Table 3, insulin-
loaded nanospheres administered orally to dia-
betic rats for 4 successive days at the concen-
tration of 50 IU/kg, improved these metabolic
parameters when compared to rats treated with
empty nanospheres. Indeed, water intake, volume
of collected urine and proteinuria over 24 h
were significantly reduced by 42 (p< 0.001),
47 (p< 0.01), and 67% (p< 0.05), respectively.
However, food intake was only slightly reducedJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 200(15%, not significant). Thus, a daily oral
administration of insulin-loaded nanospheres
for four successive days improves the metabolic
status of diabetes.DISCUSSION
The oral route of free insulin delivery takes
advantage of the portal-hepatic route of absorp-
tion. However, insulin is degraded by proteolytic
enzymes in the GIT and, being a small peptide, is
less absorbed by the intestinal mucosa. Alginate-
dextran sulfate nanospheres coated with chito-
san-PEG-albumin preserve the biological activity
of entrapped insulin, and strongly elicit an8 DOI 10.1002/jps
Figure 12. Fluorescent activity from FITC-insulin in
the intestinal content, intestinal mucosa and mesen-
teric blood after injection of albumin-chitosan-PEG
coated FITC-insulin-loaded nanospheres (50 IU/kg) in
an in situ isolated intestinal segment. Results are
expressed as meansSEM of six experiments at each
time.
NANOPARTICULATE BIOPOLYMERS DELIVER INSULIN 5301hypoglycaemic response when administered sub-
cutaneously or orally. Albumin-coating and PEG
stabilizing effect seem to be crucial in producing a
pharmacological response, as nanospheres coated
with only chitosan did not elicit hypoglycemia
following oral administration. With the newly
developed chitosan-PEG-albumin coated nano-
spheres glucose reduction was higher than 75%Table 3. Metabolic Status of Rats After Four Successive Da
(50 IU/kg)
Control
Water intake (mL/24 h) 133.0 3.6
Food intake (g/24 h) 28.8 4.1
Urine volume (mL/24 h) 118.0 11.
Proteinuria (mg/24 h) 46.0 15.
Control animals received empty nanospheres. Water and food inta
measured on urines collected for 24 h. Results are meansSEM of
p< 0.05.
p<0.01.
p< 0.001.
DOI 10.1002/jps JOURNAof basal values after an oral administration of
100 IU/kg insulin while empty nanospheres or
nonencapsulated insulin did not affect glycemia.
Glycemic response was dose-dependent and lasted
for a prolonged time, at least for 24 h, with a
maximal effect 14 h postadministration. In addi-
tion, the improvement of the glycemic response to
an oral glucose tolerance test confirms the efficacy
of orally administered particulate insulin. Finally,
plasma insulin levels increased by a factor seven
indicating that insulin was protected and well
absorbed by the intestinal mucosa.
Insulin can be incorporated into nanospheres
with high efficiency. At pH 4.5, positive amino
groups of insulin (pI¼ 5.3) strongly interact with
carboxylic groups of alginate (pKa 3.38 and 3.65)
and with sulfate groups of dextran (first pKa
negative and second pKa 2).
18 The nanoencapsu-
lation process is essential to protect insulin from
the acidic environment and proteolytic attack
during gastrointestinal tract passage. By itself,
insulin was not bioactive after oral administra-
tion. This data is not in agreement with a very
similar nanosystem which involved alginate-
chitosan nanoparticles where chitosan coating
produced an hypoglycemic response around 45%
of basal values after 14 h of oral administration.28
Albumin coating and PEG stabilizing effect
appear to play an important role on insulin
protection and particle stabilization. Protection
of nanoencapsulated insulin was demonstrated by
three experiments: firstly, insulin-loaded nano-
spheres had equivalent pharmacological activity
to nonencapsulated insulin when administered
subcutaneously; secondly, nanoparticulate insu-
lin was detected after incubation of insulin-loaded
nanospheres in presence of pepsin and thirdly,
only 25% of initial insulin content was released
from nanospheres incubated in an acidic environ-
ment simulating gastric medium, with an addi-
tional 45% being released in a neutral simulatedys Oral Administration of Insulin-Loaded Nanospheres
Insulin-Loaded Nanospheres
76.8 10.0
24.3 1.0
3 62.3 12.5
2 15.1 2.2
ke, and urine volume were measured for 24 h. Proteinuria was
six animals per group. Statistically different from control.
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5302 REIS ET AL.intestinal medium. Acid pH causes the alginate
polymer in the core of the particle to precipitate
and thus collapse, forming a tight impermeable
matrix. At subsequent neutral pH, the polymer
begins to swell, releasing the insulin.18 Therefore,
it can be considered that insulin may be partly
protected by nanospheres during passage through
the stomach. It is likely that the albumin shell
plays an important and crucial protective role
against proteolytic enzymes in the stomach.
Albumin may act as degradative target of pepsin
leaving encapsulated insulin free of proteolytic
attack. The dramatic change in zeta potential
from negative to positive, demonstrates degrada-
tion of the albumin coating, exposing the under-
lying layer of mucoadhesive chitosan and
therefore nanospheres may exert mucoadhesive
properties. As well, chitosan with PEG chains may
also influence the mesh size of the hydrogel
networks,12 forming an additional capsule shell,
made up of an interpenetrating network near the
surface of the core particle. Even if 25% of
encapsulated insulin is released in the stomach,
the main part of encapsulated insulin is active and
resistant to pepsin and will be delivered to the
intestine in its bioactive form. Since chitosan is a
polysaccharide with positive charge, it promotes
protein adsorption to the nanospheres since most
proteins have isoelectric points lower than 7.4 and
are negatively charged. In addition to particle
charge, other properties may also influence muco-
adhesion of nanospheres such as particle size and
hydrophobicity. The introduction of PEG may not
influence this property, but high concentrations
of PEG may lead to the compact nanosphere
structure as described above. PEG was also used
to improve the stability of the polymers,25,29 to
improve the half-live of insulin and to increase
residence time along the intestine.30
To enhance the intestinal absorption of peptides
and especially of insulin associated with nano-
particles, researchers generally consider several
factors: (i) mucoadhesion, (ii) particle endocytosis,
and (iii) permeation—enhancing factors.31 Muco-
adhesive properties of chitosan and PEG may
have promoted nanosphere adhesion and subse-
quent absorption by enterocytes. Measurement of
zeta potentials showed that pepsin which is
abundant in the stomach, reduced the negative
charge of insulin-loaded nanospheres, so that
nanospheres become more mucoadhesive once
in the small intestine. In fact, it was reported
that PEG chains enhanced adhesion due to the
interdiffusion and entanglements with mucusJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 200layers.32 Adhesion of insulin-loaded nanospheres
to the intestinal mucosa may improve retention
time, leading to higher concentrations of insulin
at the site of absorption.33 Previous results15 in
which positively charged insulin nanoparticles,
but of a different composition (poly(e-polycapro-
lactone)/Eudragit) are in agreement with this
assumption. We also observed a sustained dose-
dependent hypoglycemic effect in the present
study after oral administration. However, pre-
vious work 15 showed less hypoglycaemic effect
(about 40% of control values vs. 76% in the
present study) and duration of the effect was lower
(8 h vs. 14 h in the present study). Thus, it appears
that insulin-loaded nanospheres composed of
alginate-dextran sulfate coated with chitosan-
PEG-albumin exert a better antidiabetic effect
than poly(e)caprolactone-Eudragit nanoparticles
after oral administration in diabetic rats. This
difference may be explained by the polymeric
properties of the drug carriers. Indeed, the
presence of chitosan coating which confers posi-
tive charges to the nanospheres contributes to the
mucoadhesive properties of the particles and in
addition transiently opens the tight junctions20,34
allowing a better absorption of liberated or
encapsulated insulin. Moreover, a recent work28
which used negatively charged insulin nanopar-
ticles made by complexation of alginate with
chitosan led to a less pronounced hypoglycemic
response after 14 h of oral administration to
diabetic rats at dose 100 IU/kg (about 45% of
control values vs. higher than75% in the present
study). This difference may be explained by the
different methodology and by the presence of
albumin coating and PEG stabilizing effect. Our
data suggests that albumin coating is critical to
preventing pepsin attack and PEG plays an
important role as stabilizing agent.
Different mechanisms have been proposed to
explain the translocation of particulate material
across the intestinal barrier: uptake via Peyer’s
patches, isolated lymphoid follicles35–38 abundant
in the ileum, intracellular uptake via insulin
surface receptor binding39,40 and, intercellular/
paracellular passage.38,41 In order to better
approach these mechanisms of insulin absorption,
we labeled insulin with FITC and followed the
uptake by spectrofluorometry and by the observa-
tion of cryosections of the intestinal mucosa after
injection of labeled insulin-loaded nanospheres in
an in situ isolated intestinal loop. FITC-insulin
was taken up by the intestinal mucosa. Indeed,
FITC-insulin concentration decreased as a8 DOI 10.1002/jps
NANOPARTICULATE BIOPOLYMERS DELIVER INSULIN 5303function of time in the intestinal content and in
parallel increased in the intestinal mucosa and
mesenteric blood indicating that it passed from
the intestinal lumen to the blood compartment.
Fluorescence microscopic observations confirm
these data and showed at first an intense labeling
of FITC-insulin in the intestinal lumen and then
in the axis of the villi and Peyer’s patches. These
results taken together showed that insulin, either
liberated from nanospheres in the intestinal
lumen or associated with nanospheres, was able
to be taken up by the intestinal mucosa. It is
possible that a part of the insulin is liberated in
close contact with the apical part of enterocytes
then taken up by a receptor-mediated process as
described by Bendayan et al.39,40 Insulin-loaded
nanospheres may also be taken up by a para-
cellular pathway.41 Chitosan coating has been
shown to transiently open tight junctions between
cells,42 allowing the passage of small particles.
This process mainly occurs at the tip of the villi
where there is a physiological desquamation of
mature enterocytes and the presence of a thin
fluorescent film was observed overlaying the
enterocytes (Fig. 10b). However, the most intense
labeling was found in Peyer’s patches suggesting
that nanospheres may be taken up by endocytosis
through M cells. This labeling was more pro-
nounced than with poly(e)caprolactone-Eudragit
loaded insulin nanoparticles15 or with alginate-
chitosan nanoparticles28 and may be attributed to
the combination of the advantageous properties of
chitosan with those of PEG as observed by Prego
et al.29 who grafted PEG to chitosan.
In addition, this formulation had beneficial
effects on diabetic symptoms, including thirst,
frequent urination and proteinuria. Thirst devel-
ops because of osmotic effects as sufficiently high
glucose above the renal threshold in the blood is
excreted by the kidneys. This requires water
causing increased fluid loss, which must be
replaced. The lost blood volume will be replaced
from water held inside body cells, causing
dehydration. Water intake (polydipsia) was sig-
nificantly reduced in a 4-day period due to lower
glycemia levels following insulin-nanosphere
administration. As well, polyuria was signifi-
cantly reduced after 4 days of daily administra-
tion. Additional metabolic studies will be
performed in order to characterize the metabolic
and toxicological effects during continuous and
prolonged oral administration. The potential
extension to other therapeutic proteins will also
be studied in the next future.DOI 10.1002/jps JOURNACONCLUSIONS
Alginate-dextran sulfate core, chitosan-polyethy-
lene glycol-albumin coated nanospheres protect
insulin during nanosphere formulation and from
proteolytic degradation during gastrointestinal
transit. Insulin-loaded nanospheres with small
size (50% less than 812 nm) and encapsulation
efficiency of 85% were produced by emulsion
dispersion/triggered gelation, followed by poly-
electrolyte coating. Blood glucose reduction fol-
lowing oral administration was higher than 70%
of the basal value while empty nanospheres
or nonencapsulated insulin were ineffective in
producing oral hypoglycemic response. Nano-
spheres lacking albumin and PEG in the coating
material were also ineffective, as it appears that
albumin prevents protease attack on the insulin,
and PEG serves as nanosphere stablizer. In
contrast, chitosan-PEG-albumin coated nano-
spheres increased insulinemia by a factor of seven
and significantly improved the response to the
glucose oral tolerance test. Insulin-loaded nano-
spheres exert an antidiabetogenic effect when
administered perorally in diabetic rats and show
high intestinal uptake by Peyer’s Patches and
villi. The excipients used are well accepted in the
pharmaceutical field, thus this formulation is able
to markedly improve the intestinal absorption of
insulin and will be of interest in the treatment
of diabetes with oral insulin. The benefits are
considerable in terms of diabetes, but also
potentially toward the oral delivery of many other
therapeutic peptides and proteins.ACKNOWLEDGMENTS
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